452 related articles for article (PubMed ID: 34298929)
1. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
[TBL] [Abstract][Full Text] [Related]
2. New insights into ANGPLT3 in controlling lipoprotein metabolism and risk of cardiovascular diseases.
Su X; Peng DQ
Lipids Health Dis; 2018 Jan; 17(1):12. PubMed ID: 29334984
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological aspects of ANGPTL3 and ANGPTL4 inhibitors: New therapeutic approaches for the treatment of atherogenic dyslipidemia.
Ruscica M; Zimetti F; Adorni MP; Sirtori CR; Lupo MG; Ferri N
Pharmacol Res; 2020 Mar; 153():104653. PubMed ID: 31931117
[TBL] [Abstract][Full Text] [Related]
4. The Citrus Flavonoid Nobiletin Downregulates Angiopoietin-like Protein 3 (ANGPTL3) Expression and Exhibits Lipid-Modulating Effects in Hepatic Cells and Adult Zebrafish Models.
Lin CY; Chen PY; Hsu HJ; Gao WY; Wu MJ; Yen JH
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293338
[TBL] [Abstract][Full Text] [Related]
5. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol.
Xu YX; Redon V; Yu H; Querbes W; Pirruccello J; Liebow A; Deik A; Trindade K; Wang X; Musunuru K; Clish CB; Cowan C; Fizgerald K; Rader D; Kathiresan S
Atherosclerosis; 2018 Jan; 268():196-206. PubMed ID: 29183623
[TBL] [Abstract][Full Text] [Related]
6. The Lipid-Modulating Effect of Tangeretin on the Inhibition of Angiopoietin-like 3 (ANGPTL3) Gene Expression through Regulation of LXRα Activation in Hepatic Cells.
Chen PY; Chao TY; Hsu HJ; Wang CY; Lin CY; Gao WY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576019
[TBL] [Abstract][Full Text] [Related]
7. ANGPTL3 as therapeutic target.
Kersten S
Curr Opin Lipidol; 2021 Dec; 32(6):335-341. PubMed ID: 34581310
[TBL] [Abstract][Full Text] [Related]
8. ANGPTL3 is part of the machinery causing dyslipidemia majorily via LPL inhibition in mastitis mice.
Xiao HB; Wang JY; Sun ZL
Exp Mol Pathol; 2017 Dec; 103(3):242-248. PubMed ID: 29104012
[TBL] [Abstract][Full Text] [Related]
9. Angiopoietin-like 3 in lipoprotein metabolism.
Kersten S
Nat Rev Endocrinol; 2017 Dec; 13(12):731-739. PubMed ID: 28984319
[TBL] [Abstract][Full Text] [Related]
10. ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis.
Mohamed F; Mansfield BS; Raal FJ
Curr Atheroscler Rep; 2022 Dec; 24(12):959-967. PubMed ID: 36367663
[TBL] [Abstract][Full Text] [Related]
11. ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys.
Gusarova V; Alexa CA; Wang Y; Rafique A; Kim JH; Buckler D; Mintah IJ; Shihanian LM; Cohen JC; Hobbs HH; Xin Y; Valenzuela DM; Murphy AJ; Yancopoulos GD; Gromada J
J Lipid Res; 2015 Jul; 56(7):1308-17. PubMed ID: 25964512
[TBL] [Abstract][Full Text] [Related]
12. Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia.
Shoji T; Hatsuda S; Tsuchikura S; Kimoto E; Kakiya R; Tahara H; Koyama H; Emoto M; Tabata T; Nishizawa Y
Atherosclerosis; 2009 Dec; 207(2):579-84. PubMed ID: 19540497
[TBL] [Abstract][Full Text] [Related]
13. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8.
Sylvers-Davie KL; Davies BSJ
Am J Physiol Endocrinol Metab; 2021 Oct; 321(4):E493-E508. PubMed ID: 34338039
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
[TBL] [Abstract][Full Text] [Related]
15. Triglyceride-rich lipoproteins, apolipoprotein C-III, angiopoietin-like protein 3, and cardiovascular events in older adults: Atherosclerosis Risk in Communities (ARIC) study.
Hussain A; Sun C; Selvin E; Nambi V; Coresh J; Jia X; Ballantyne CM; Hoogeveen RC
Eur J Prev Cardiol; 2022 Mar; 29(2):e53-e64. PubMed ID: 33580780
[TBL] [Abstract][Full Text] [Related]
16. Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits.
Mehta N; Qamar A; Qu L; Qasim AN; Mehta NN; Reilly MP; Rader DJ
Arterioscler Thromb Vasc Biol; 2014 May; 34(5):1057-63. PubMed ID: 24626437
[TBL] [Abstract][Full Text] [Related]
17. A novel fully human anti-NT-ANGPTL3 antibody from phage display library exhibits potent ApoB, TG, and LDL-C lowering activities in hyperlipidemia mice.
Zhang P; Wang K; Hu T; Xu M; You X; Chen M; Tang X; Hu H; Jiang Y; Zhao W; Tan S
FASEB J; 2024 Jan; 38(1):e23399. PubMed ID: 38174870
[TBL] [Abstract][Full Text] [Related]
18. Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation.
Athyros VG; Katsiki N; Dimakopoulou A; Patoulias D; Alataki S; Doumas M
Curr Pharm Des; 2018; 24(31):3638-3646. PubMed ID: 30306859
[TBL] [Abstract][Full Text] [Related]
19. ANGPTL3 (Angiopoietin-Like 3) Preferentially Resides on High-Density Lipoprotein in the Human Circulation, Affecting Its Activity.
Kraaijenhof JM; Tromp TR; Nurmohamed NS; Reeskamp LF; Langenkamp M; Levels JHM; Boekholdt SM; Wareham NJ; Hoekstra M; Stroes ESG; Hovingh GK; Grefhorst A
J Am Heart Assoc; 2023 Nov; 12(21):e030476. PubMed ID: 37889183
[TBL] [Abstract][Full Text] [Related]
20. ANGPTL3 deficiency alters the lipid profile and metabolism of cultured hepatocytes and human lipoproteins.
Ruhanen H; Haridas PAN; Minicocci I; Taskinen JH; Palmas F; di Costanzo A; D'Erasmo L; Metso J; Partanen J; Dalli J; Zhou Y; Arca M; Jauhiainen M; Käkelä R; Olkkonen VM
Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Jul; 1865(7):158679. PubMed ID: 32151767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
